BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» 'Worst-Case Scenario': VaxGen Ends Planned Merger with Raven
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
'Worst-Case Scenario': VaxGen Ends Planned Merger with Raven
March 31, 2008
By
Jennifer Boggs
No Comments
Despite attempts to quell grumblings from some of its stockholders over the last three months, troubled VaxGen Inc. ended its agreement to merge with Raven Biotechnologies, citing "stronger than anticipated" opposition to deal. (BioWorld Today)
BioWorld